Come and find out what we have in the pipeline and explore those indications where our technology is set to have the greatest clinical benefit.
Home - Pipeline
What's in the pipeline?
Indication
Short Description
Pre-clinical discovery
Pre-clinical development
Phase I/IIa
Phase IIb
Phase III
Status
Mechanism
Recessive dystrophic epidermolysis bullosa (RDEB) a b c d 1
Genetic disorder with systemic inflammation and severe wounds, reduced life expectancy
Recruiting
(more info)
Anti-inflammation
Non-healing chronic venous wounds (CVU) 2 3
Non-healing wound from venous insufficiency
Recruiting
(more info)
Anti-inflammation
Non-healing diabetic foot ulcers (DFU)
Non-healing wound as diabetic complication
In set up
Anti-inflammation
Acute graft-versus-host disease (GvHD)
Severe immune response caused by bone-marrow transplant, potential fatal
Ongoing
Anti-inflammation
Polycystic kidney disease (PKD)
Genetic disorder resulting in renal failure with potential fatal outcome
Ongoing
Anti-inflammation and Regeneration
Transplant rejection
Complication caused by immune-system overreaction
Ongoing
Anti-inflammation
1 EBESANAR®
2 Marketing authorization in Germany granted for AMESANAR®
3 RHEACELL's cell therapy product AMESANAR® is listed on the website of Germany's Federal Institute for Vaccines and Biomedicines (competent authority)
a Orphan Drug Designation FDA
b Orphan Drug Designation EMA
c Pediatric Investigation Plan (PIP) approved by PDCO (EMA)
d RMAT Designation FDA